AzTrials
AzTrials

Multiple SclerosisNCT07423312

Lead Exposure and Multiple Sclerosis

An observational study of Multiple Sclerosis, run by Assiut University.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

1. To evaluate the effect of lead level on the pathogenesis of multiple sclerosis 2. Measure lead in blood sample of study groups 3. Estimate the expression level of DNA methyltransferase. 4. Evaluate oxidative stress markers, like MDA/8-OHdG 5. Measureδ-aminolevulinic acid 6. Read more about this study

Who is it for?
Ages 20 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Multiple Sclerosis
How many people
140 participants
Where
No sites listed yet
Study dates
30 Dec 2026to 5 May 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: 20-50 years old ,matched age ad sex

Who may be able to join

  • patients aged20-50 years diagnosed MS patients according to Mc Donald criteria

Who cannot join

  • other autoimmune disease Chronic renal or liver disease

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Asmaa Mohammed Aref, domenestrator contact

+201012061829

asmaaaref@aun.edu.eg

About this study

Official title: Lead Exposure and Multiple Sclerosis;Biomarker Evidance and Clinical Impact.

  1. To evaluate the effect of lead level on the pathogenesis of multiple sclerosis
  2. Measure lead in blood sample of study groups
  3. Estimate the expression level of DNA methyltransferase.
  4. Evaluate oxidative stress markers, like MDA/8-OHdG
  5. Measureδ-aminolevulinic acid
  6. Correlate the clinical data of patients with biochemical markers
Read the detailed description

inflammation, demyelination, gliosis, and neuronal loss are all components of multiple sclerosis (MS), a chronic autoimmune disease that affects the central nervous system (CNS). Myelinated axons in the CNS are the target of MS attacks, which can cause varying degrees of damage to both myelin and axons.MS affects 2.3 million people worldwide. MS is often diagnosed between the ages of 20 and 50 years, with females experiencing it more often than males. Four MS phenotypes exist: clinically isolated syndrome, relapsing-remitting (RRMS), secondary progressive and primary progressive.Many factors have been found to be associated, including environmental toxins..Pathological features that require explanation are the presence of demyelination in both white and grey matter , the targeting of oligodendrocytes, damage to the blood-brain barrier, inflammation in MS plaques and in the meninges, astrocyte activation, the central role of blood vessels and their perivascular spaces, and the presence of oxidative stress, mitochondrial damage, and oligodendrocyte apoptosis.Oxidative Stress and MS

.the oxidative damage of oligodendrocytes and neurons is associated with inflammation, and play a major role in neurodegeneration.Many autopsy studies describe an increase in various markers of lipid peroxidation, markers of DNA damage.CSF levels of trace metals involved in oxidative stress processes were the subject of a single study, which described increased lead, decreased magnesium, and similar calcium, manganese, and zinc levels in patients with primary progressive MS (PPMS) compared to those with secondary progressive MS (SPMS) and controls. lead(Pb) is a well-known toxic metal that threatens public health and is widely involved in the pathogenesis of MS. Accumulation of Pb in cells has been associated with the development of autoantibodies against different cellular structures such as neurofilaments, neuronal cytoskeletal proteins, and myelin basic protein.Lead exposure primarily occurs through ingesting tainted food or water, or inhaling Pb-contaminated air.The primary sources of occupational Pb exposure include the production of paint, recycling of batteries, wood preservation, welding, textile, printing, and handicraft industry . Some other sources, like canned food, cosmetics, lead pipes for water supply, and use of herbal products, also lead to Pb exposure in humans.The specific pathophysiological mechanisms mediating the relationship between environmental risk factors and MS susceptibility remain unknown, and DNA methylation may provide information on these mechanisms.This epigenetic pathway contributes to various MS pathophysiological processes, such as demyelination and remyelination, inflammatory response, and the collapse of the blood brain barrier (BBB).Research shows that lead has a deleterious impact on the immune system and is an important factor in inflammation. Lead also impacts cytokine metabolism (interleukins IL-1b, IL-4, IL-2, IL-8, and IL-6), TNF-α and INF-γ, and the expression of inflammatory enzymes (cyclooxygenases). Numerous studies have examined the impact of lead on immune system cells, including macrophages, B and T lymphocytes, and Langerhans cells. However, the impact depends on the kind of lead, dosage, route of entry, exposure period, age, host and genetic predisposition.Mechanisms by which lead may contribute to MS pathogenesis

  1. oxidative stress (increased reactive oxygen species (ROS)/ malonyldialdehyde( MDA)/[8-Hydrox-2-deoxyguanosine( 8-oHdG)])
  2. Immune system dysregulation (activation of microglia/shift toward pro-inflammatory cytokines IL-6,TNF-a)
  3. Blood brain barrier disruption (lead increase BBB permeability)
  4. Epigenetic effects (effect DNA methyltransferase/altered gene expression lead to autoimmunity) Therefore, studyig the effect of lead exposure on pathogenesis of multiple sclerosis is of great importance.
Medical subject headings
Multiple Sclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07423312
Study groupRoleWhat they receive
healthy groupNot described
multiple sclerosis groupNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measure concentration of blood lead level in multiple sclerosis patients and controls, assessed with biochemical analysis

    Measured: 2years

  2. Measure levels of oxidative stress markers like MDA/8-OHdG assay using biochemical analysis.

    Measured: 2years

  3. Measure levels of DNA methyl transferase expression level (evaluate oxidative stress-mediated epigenetic change) using PCR.

    Measured: 2years

  4. Measure δ-aminolevulinic acid levels via biochemical analysis.

    Measured: 2years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Feb 2026
  2. Study start30 Dec 2026 (estimated)
  3. Primary completion30 Dec 2028 (estimated)
  4. Study completion5 May 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
140 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07423312
Sponsor's protocol ID
lead and multiple sclerosis
Status last verified
Feb 2026
First submitted
11 Feb 2026
Last updated
20 Feb 2026
Results posted
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Multiple Sclerosis, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 20 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Asmaa Mohammed Aref, domenestrator (+201012061829, asmaaaref@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measure concentration of blood lead level in multiple sclerosis patients and controls, assessed with biochemical analysis (time frame: 2years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in